Endonovo Therapeutics Inc (ENDV)

[srinsocal]

This was the last statement on an Uplist:

LOS ANGELES, CA--(Marketwired - November 28, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing to redeem all of its outstanding convertible notes, fund several pre-clinical studies targeting vascular diseases and ischemic injuries in vital organs and to prepare to uplist the Company's common stock onto a national stock exchange.

The financing, subject to the signing of a definitive agreement, will be used to buy back approximately $2.2 million in Company convertible notes in order to preserve shareholder value, prevent additional dilution from the conversion of notes payable and to strengthen the Company's balance sheet. The strategic healthcare investor is serving as lead investor in a larger $15 million proposed financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017.

"It is very important that we buy back all outstanding convertible notes in order to prevent dilution and preserve shareholder value. We believe that our stock is considerably undervalued," continued Mr. Collier.

"This round of financing allows us to fund our the development of portfolio of treatments targeting vascular diseases and ischemic injuries and strengthens our financial position to uplist our common stock onto a national stock exchange in the first half of next year," concluded Mr. Collier.

http://www.biospace.com/news_story.aspx?StoryID=440436